SNIPR receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women

SNIPR receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR's microbial gene therapy platform to improve EED in pregnant women from low- and middle-income countries (LMICs).

Press release

Previous
Previous

SNIPR receives up to EUR 20 million from European Investment Bank (EIB) to advance therapies against microbial resistance

Next
Next

SNIPR receives USD 5.48 million funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials